Los Angeles startup closes largest round yet as employers search for ways to decode—and reduce—healthcare costs
The healthcare industry spent years fighting transparency mandates. Now a small Los Angeles startup is wagering that all those price lists insurers were forced to publish might actually be worth something.
Handl Health closed a $14.2 million Series A on February 24, the largest funding round to date for the Culver City company that transforms federally mandated pricing files into what it describes as actionable intelligence for benefits consultants. Arthur Ventures led the investment, joined by Syndra Capital Partners, an undisclosed strategic investor, and a roster of existing backers including Mucker Capital, Riverfront Ventures, and Digital Health Venture Partners.
An SEC filing reveals 23 investors committed $14,211,328 in total, with the first tranche closing December 31. The capital brings Handl's total raised to just over $20 million across 11 funding events since the company's 2022 launch—a figure that includes a $2.5 million seed round last April and a $1.3 million National Institutes of Health grant.
Making Sense of a Trillion Data Points
The premise is straightforward, if audacious. Since July 2022, federal Transparency in Coverage rules have required health plans to publish machine-readable files detailing negotiated rates with providers. The result: a sprawling, often unwieldy trove of pricing data that most employers lack the tools to interpret—or the time to parse.
Handl built what it bills as the "first-to-market AI platform" to do exactly that. Its Iris analytics tool ingests pricing data from more than 1,000 health plans, covering upwards of 4,000 hospitals and 3 million providers. The company claims to have assembled a repository exceeding one trillion data points, which benefits consultants can query to reprice claims, compare network options, and model alternative plan designs.
According to Handl, the platform has identified $113 million in potential savings across roughly $1 billion in client spending over two years. Alternative plan designs, the company says, have delivered cost reductions of 22 percent on what the industry calls "shoppable procedures"—elective services where price comparisons are feasible. Brokers use the system to validate carrier proposals and run real-time "what-if" scenarios, with outputs displayed in both dollar figures and as percentages of Medicare rates.
Whether those savings materialize in practice, or remain theoretical projections on a consultant's dashboard, is harder to verify.
Timing Meets Urgency
The round arrives at a moment when employers are, once again, bracing for sharp increases in health costs. Mercer projects growth between 5.8 and 6.5 percent for 2025; some 2026 forecasts push as high as 9.5 percent. Meanwhile, hospitals continue to command premiums well above Medicare benchmarks. A 2022 RAND Corporation study found private insurers paying hospitals an average of 254 percent of Medicare rates—up from 224 percent just two years earlier.
Arthur Ventures, an early-stage B2B software investor managing approximately $2 billion, framed the deal as a wager on the convergence of artificial intelligence and newly mandated pricing transparency. "The data is finally there," the logic goes. Now comes the harder part: making it useful.
Handl will face competition in a field that's grown more crowded. Turquoise Health, which secured $20 million from Andreessen Horowitz in 2022, is pursuing a similar thesis. Larger consulting houses—Aon, Willis Towers Watson, Marsh McLennan—have rolled out their own enterprise tools. And a parade of HR tech startups are angling for a piece of the benefits administration market, each promising to demystify healthcare pricing in its own way.
What the Money Buys
Handl says it will deploy the new capital to expand platform capabilities and refine its plan analytics, with an eye toward improving benefit design and cost predictability. The company graduated from Techstars Healthcare Accelerator in 2023 and BrokerTech Ventures last year. It employs between 11 and 50 people, according to public records, though the company declined to provide a precise headcount.
For Arthur Ventures and its co-investors, the bet hinges on a question that has vexed the American healthcare system for decades: Can transparency actually bend the cost curve? Federal regulators thought mandating price disclosures might help. Handl is betting it can turn that regulatory requirement into a business.
Whether consultants—and ultimately, employers—will pay for the privilege of understanding what they're already paying for remains to be seen.
